ECSP055918A - Procedimiento para modificar la formación de cristal de fármaco - Google Patents

Procedimiento para modificar la formación de cristal de fármaco

Info

Publication number
ECSP055918A
ECSP055918A EC2005005918A ECSP055918A ECSP055918A EC SP055918 A ECSP055918 A EC SP055918A EC 2005005918 A EC2005005918 A EC 2005005918A EC SP055918 A ECSP055918 A EC SP055918A EC SP055918 A ECSP055918 A EC SP055918A
Authority
EC
Ecuador
Prior art keywords
modify
procedure
formation
methods
drug glass
Prior art date
Application number
EC2005005918A
Other languages
English (en)
Inventor
Sabine Pfeffer
Dierk Wieckhusen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9951448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP055918(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP055918A publication Critical patent/ECSP055918A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Se describe un procedimiento para modificar el hábito de cristal de sustancias de fármaco aciculares, cristales obtenidos a través de dicho procedimiento, y formas de cristal particulares o modificaciones de ácido micofenólico o micofenolato de sodio, así como composiciones farmacéuticas que comprenden los cristales, métodos y tratamiento y usos de los mismos.
EC2005005918A 2003-01-20 2005-07-15 Procedimiento para modificar la formación de cristal de fármaco ECSP055918A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0301259.8A GB0301259D0 (en) 2003-01-20 2003-01-20 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP055918A true ECSP055918A (es) 2005-11-22

Family

ID=9951448

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005918A ECSP055918A (es) 2003-01-20 2005-07-15 Procedimiento para modificar la formación de cristal de fármaco

Country Status (31)

Country Link
US (3) US20060122265A1 (es)
EP (2) EP2308471A1 (es)
JP (1) JP4549976B2 (es)
KR (5) KR101129105B1 (es)
CN (2) CN101333201A (es)
AR (2) AR043343A1 (es)
AT (1) ATE546132T1 (es)
AU (1) AU2004206731B2 (es)
BR (1) BRPI0406827A (es)
CA (2) CA2706900A1 (es)
CL (1) CL2004000073A1 (es)
CO (1) CO5580738A2 (es)
CY (1) CY1112772T1 (es)
DK (1) DK1592401T3 (es)
EC (1) ECSP055918A (es)
ES (1) ES2382035T3 (es)
GB (1) GB0301259D0 (es)
IL (1) IL169484A (es)
MX (1) MXPA05007691A (es)
MY (1) MY148297A (es)
NO (1) NO20053846L (es)
NZ (1) NZ541073A (es)
PE (2) PE20110276A1 (es)
PL (2) PL376525A1 (es)
PT (1) PT1592401E (es)
RU (1) RU2388757C2 (es)
SG (1) SG155046A1 (es)
SI (1) SI1592401T1 (es)
TW (1) TWI325785B (es)
WO (1) WO2004064806A2 (es)
ZA (1) ZA200504442B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
JP2007532585A (ja) 2004-04-26 2007-11-15 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ ミコフェノール酸及びそのエステル誘導体の調製方法
EP1740563A2 (en) 2004-04-27 2007-01-10 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Mycophenolate mofetil impurity
JP2008506784A (ja) * 2004-07-20 2008-03-06 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ 結晶形ミコフェノール酸・ナトリウム
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20080176937A1 (en) * 2007-01-23 2008-07-24 Apotex Fermentation Inc. Novel crystalline mycophenolate sodium polymorph and processes to manufacture same
MX2011003731A (es) * 2008-10-09 2011-08-03 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Uso de solventes organicos en la granulacion humeda de moxifloxacino.
CN101756958B (zh) * 2008-11-10 2011-07-20 鲁南制药集团股份有限公司 一种治疗关节炎的药物组合物及其制备方法
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
US8772512B2 (en) * 2009-07-10 2014-07-08 Janssen Pharmaceutica Nv Crystallisation process for 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene
WO2011046546A1 (en) * 2009-10-13 2011-04-21 Teva Pharmaceutical Industries Ltd. Delayed release compositions
CN108558740B (zh) 2010-01-27 2021-10-19 艾尼纳制药公司 S1p1受体调节剂及其盐的制备方法
ES2596291T3 (es) 2010-05-11 2017-01-05 Janssen Pharmaceutica, N.V. Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
CN103880799A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103880800A (zh) * 2010-11-16 2014-06-25 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
CN103596944B (zh) 2011-04-13 2017-02-22 詹森药业有限公司 可用作sglt2的抑制剂的化合物的制备方法
TWI582078B (zh) * 2013-01-23 2017-05-11 北京貝美拓新藥研發有限公司 抑制脯氨酸羥化酶活性的化合物的晶型及其應用
HUE060476T2 (hu) 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
LT3394051T (lt) * 2015-12-21 2020-08-10 Janssen Pharmaceutica N.V. Kristalizacijos procedūra, skirta kanagliflozino hemihidrato kristalų gavimui
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CN108727317A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 一种麦考酚酸的晶型物
CN108727318A (zh) * 2017-04-25 2018-11-02 鲁南制药集团股份有限公司 麦考酚酸的晶型物
US12156866B2 (en) 2018-06-06 2024-12-03 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
CN110922371B (zh) * 2019-12-27 2020-08-11 广东蓝宝制药有限公司 一种m2晶型麦考酚钠的制备方法
WO2021234544A1 (en) 2020-05-18 2021-11-25 Novartis Ag Crystalline form of lnp023
KR20250013155A (ko) * 2022-05-31 2025-01-31 혼슈우 카가쿠고교 가부시키가이샤 4,4'－비스(1,1－비스(4－히드록시－3－메틸페닐)에틸)비페닐의 결정 및 그의 제조방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US158835A (en) * 1875-01-19 Improvement in mortising-tools
GB935432A (en) * 1958-05-29 1963-08-28 Secr Aviation Improvements in the manufacture of crystalline substances
US3183263A (en) * 1962-10-19 1965-05-11 Commercial Solvents Corp Method for changing the crystal habit of mono-sodium glutamate
US3187039A (en) * 1962-10-19 1965-06-01 Commercial Solvents Corp Method for changing the crystal habit of monosodium glutamate
US3352906A (en) * 1963-02-04 1967-11-14 Charles R Parkerson Habit modification and preparation of single crystal triglycine sulfate
GB1157099A (en) * 1966-09-27 1969-07-02 Ici Ltd Fermentation Process
GB1157100A (en) * 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
US3770390A (en) * 1971-02-26 1973-11-06 Dow Chemical Co Crystal habit modification of inorganic salts using polymeric sulfonates or sulfates
US4259239A (en) * 1980-04-21 1981-03-31 Allied Chemical Corporation Resolution of enantiomeric complexes of nickelous chloride and alpha-aminocaprolactam
IL60254A (en) 1980-06-08 1983-11-30 Yeda Res & Dev Resolution of amino acids
JPS5875194A (ja) * 1981-10-30 1983-05-06 株式会社日立製作所 マトリクス表示装置及び駆動方法
JPS59232916A (ja) * 1983-06-16 1984-12-27 Shiraishi Chuo Kenkyusho:Kk 針柱状炭酸カルシウム結束体、その製造法及び該結束体を含有する感熱紙用塗被組成物
IL77031A (en) 1985-11-12 1995-12-08 Yeda Res & Dev Kinetic resolution of racemic mixtures by polymer-bound crystallization inhibitors
JPH0745359B2 (ja) 1987-12-25 1995-05-17 東レ株式会社 有機化合物結晶の製造方法
EP0582452B1 (en) * 1992-08-04 1998-10-14 Toda Kogyo Corp. Granulated particles for magnetic particles for magnetic recording and process for producing the same
PL178522B1 (pl) 1993-09-15 2000-05-31 Syntex Inc Krystaliczny, bezwodny związek, mykofenolan mofetylu, kompozycja odpowiednia do sporządzania wodnego preparatu dożylnego, sposób wytwarzania kompozycji odpowiedniej do sporządzania preparatu dożylnego i zestaw użyteczny do sporządzania dożylnego preparatu
JPH09209297A (ja) * 1996-01-26 1997-08-12 Nippon Paper Ind Co Ltd 艶消し軽量塗工紙及びその製造方法
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
KR100491274B1 (ko) * 1996-04-12 2005-09-05 노파르티스 아게 미코페놀레이트의장용코팅된약제조성물
FR2780403B3 (fr) * 1998-06-24 2000-07-21 Sanofi Sa Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US8008511B2 (en) 2011-08-30
US8124795B2 (en) 2012-02-28
PE20040826A1 (es) 2004-12-23
AU2004206731B2 (en) 2008-03-20
AR103711A2 (es) 2017-05-31
PT1592401E (pt) 2012-05-10
KR20050096940A (ko) 2005-10-06
WO2004064806A2 (en) 2004-08-05
KR20090115898A (ko) 2009-11-09
SG155046A1 (en) 2009-09-30
ATE546132T1 (de) 2012-03-15
CL2004000073A1 (es) 2005-01-14
BRPI0406827A (pt) 2005-12-27
NZ541073A (en) 2008-12-24
JP4549976B2 (ja) 2010-09-22
US20110288313A1 (en) 2011-11-24
AU2004206731A1 (en) 2004-08-05
US20090209639A1 (en) 2009-08-20
RU2388757C2 (ru) 2010-05-10
PL376525A1 (pl) 2006-01-09
AU2004206731A8 (en) 2004-08-05
ZA200504442B (en) 2006-02-22
ES2382035T3 (es) 2012-06-04
IL169484A0 (en) 2007-07-04
PE20110276A1 (es) 2011-05-27
CN101333201A (zh) 2008-12-31
CA2706900A1 (en) 2004-08-05
GB0301259D0 (en) 2003-02-19
RU2005126328A (ru) 2006-07-27
AR043343A1 (es) 2005-07-27
KR101129105B1 (ko) 2012-04-12
EP1592401B1 (en) 2012-02-22
PL393385A1 (pl) 2011-03-14
US20060122265A1 (en) 2006-06-08
MXPA05007691A (es) 2005-09-30
IL169484A (en) 2016-03-31
NO20053846L (no) 2005-08-16
JP2006515016A (ja) 2006-05-18
CO5580738A2 (es) 2005-11-30
PL213192B1 (pl) 2013-01-31
WO2004064806A3 (en) 2004-10-28
KR20090115821A (ko) 2009-11-06
CN100595199C (zh) 2010-03-24
TWI325785B (en) 2010-06-11
CA2509796C (en) 2010-09-14
KR20100120321A (ko) 2010-11-15
EP1592401A2 (en) 2005-11-09
CY1112772T1 (el) 2016-02-10
KR100855149B1 (ko) 2008-08-28
KR20070087181A (ko) 2007-08-27
EP2308471A1 (en) 2011-04-13
TW200505505A (en) 2005-02-16
CN1738605A (zh) 2006-02-22
MY148297A (en) 2013-03-29
HK1084874A1 (en) 2006-08-11
CA2509796A1 (en) 2004-08-05
SI1592401T1 (sl) 2012-05-31
DK1592401T3 (da) 2012-05-21

Similar Documents

Publication Publication Date Title
ECSP055918A (es) Procedimiento para modificar la formación de cristal de fármaco
ECSP19076732A (es) Compuestos de heteroarilo bicíclicos 6–6 fusionados y su uso como inhibidores de lats
PE20050255A1 (es) Nuevas cianotiazolidas y procedimiento para su preparacion como medicamentos
BR0207726A (pt) Sais farmacêuticos
EA200501222A1 (ru) Дигидроптеридиноны, способ их получения и их применение в качестве лекарственных средств
BRPI0315296B8 (pt) derivados do ciclohexanol espirocíclicos, medicamento incluindo pelo menos um derivado do ciclohexano espirocíclico e uso de um derivado do ciclohexano espirocíclico
BRPI0414541A8 (pt) compostos heterocíclicos fundidos, seu uso, método de preparação de compostos intermediários e método para estudar distúrbios mediados por serotonina
BRPI0413197A (pt) cristal de eta wercept; método para fabricar um cristal de etanercept; composição; uso de um cristal de etanercept
BRPI0611350B8 (pt) formulação, seus usos e seu processo de fabricação,e artigo de fabricação
BRPI0406913A (pt) Dispersão de cristais de sabor mascarado ou de grânulos de substâncias ativas, cápsulas macias mascáveis preenchidas com a referida dispersão, e processo para a preparação da mesma
BRPI0409454A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com o receptor de glucagon e sua utilização
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
UY29002A1 (es) Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
ATE450501T1 (de) Pentafluorsulfanyl-substituierte verbindung und deren verwendung zur herstellung von arzneimitteln
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
ECSP066770A (es) Nuevos ésteres de quinuclidina cuaternizados
BRPI0517032A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos
EA200601845A1 (ru) НОВЫЕ β-АГОНИСТЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ
UY27733A1 (es) Derivados de ciclopenteno.
PE20020907A1 (es) Combinacion de taxano y una cinasa dependiente de la ciclina
EA200701178A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
BRPI0507745A (pt) compostos de azetidina substituìda como inibidores de ciclooxigenase-1-ciclooxigenase-2, processo para a sua preparação, medicamentos e seus usos